ID

23028

Description

NCT00340080 / VIIV-CNA106030 https://clinicaltrials.gov/ct2/show/NCT00340080 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Day 1 (Cohort Study) Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Lien

https://clinicaltrials.gov/ct2/show/NCT00340080

Mots-clés

Versions (1)
  1. 20/06/2017 20/06/2017 -
Téléchargé le

20 juin 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Genetic Screening For HLA-B*5701 n Patients with HIV Day 1 NCT00340080

Anglais

Genetic Screening For HLA-B*5701 Day 1 NCT00340080

1 Formulaires  
Day 1
Description

Day 1

Alias
UMLS CUI-1
C1516637
UMLS CUI-2
C0009247
Subject Identifier
Description

Subject Identifier

Type de données

text

Alias
UMLS CUI [1]
C2348585
Visit Date
Description

Visit Date

Type de données

date

Alias
UMLS CUI [1]
C1320303
Is subject going to be followed prospectively in the cohort sub-study of HLA-B*5701 positive subjects?
Description

cohort sub-study

Type de données

text

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C0009247
Has the subject previously received and permanently stopped antiretroviral therapy prior to Day 1?
Description

If Yes, record each medication on a separate line using Trade Names where possible.

Type de données

text

Alias
UMLS CUI [1]
C1963724
Drug Name (Trade name preferred)
Description

If Yes, record each medication on a separate line using Trade Names where possible.

Type de données

text

Alias
UMLS CUI [1,1]
C2360065
UMLS CUI [1,2]
C1963724
Start Date
Description

If Yes, record each medication on a separate line using Trade Names where possible.

Type de données

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C1963724
Stop Date
Description

If Yes, record each medication on a separate line using Trade Names where possible.

Type de données

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C1963724
Ongoing Medication?
Description

If Yes, record each medication on a separate line using Trade Names where possible.

Type de données

text

Alias
UMLS CUI [1,1]
C2826666
UMLS CUI [1,2]
C1963724
Vital signs: Blood pressure systolic
Description

Blood pressure systolic

Type de données

integer

Unités de mesure
  • mmHg
Alias
UMLS CUI [1]
C0871470
mmHg
Vital signs: Blood pressure diastolic
Description

Blood pressure diastolic

Type de données

integer

Unités de mesure
  • mmHg
Alias
UMLS CUI [1]
C0428883
mmHg
Vital signs: Heart rate
Description

Heart rate

Type de données

integer

Unités de mesure
  • beats/minute
Alias
UMLS CUI [1]
C0018810
beats/minute
Vital signs: Temperature
Description

Temperature

Type de données

float

Unités de mesure
  • °C
Alias
UMLS CUI [1]
C0005903
°C
Retour au début de la page

Similar models

Genetic Screening For HLA-B*5701 Day 1 NCT00340080

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Day 1
C1516637 (UMLS CUI-1)
C0009247 (UMLS CUI-2)
Subject Identifier
Item
Subject Identifier
text
C2348585 (UMLS CUI [1])
Visit Date
Item
Visit Date
date
C1320303 (UMLS CUI [1])
Item
Is subject going to be followed prospectively in the cohort sub-study of HLA-B*5701 positive subjects?
text
C1516637 (UMLS CUI [1,1])
C0009247 (UMLS CUI [1,2])
Eligibility Question
Code List
Is subject going to be followed prospectively in the cohort sub-study of HLA-B*5701 positive subjects?
CL Item
Yes (Y)
CL Item
No (N)
Item
Has the subject previously received and permanently stopped antiretroviral therapy prior to Day 1?
text
C1963724 (UMLS CUI [1])
Eligibility Question
Code List
Has the subject previously received and permanently stopped antiretroviral therapy prior to Day 1?
CL Item
Yes (Y)
CL Item
No (N)
Drug Name
Item
Drug Name (Trade name preferred)
text
C2360065 (UMLS CUI [1,1])
C1963724 (UMLS CUI [1,2])
Start Date
Item
Start Date
date
C0808070 (UMLS CUI [1,1])
C1963724 (UMLS CUI [1,2])
Stop Date
Item
Stop Date
date
C0806020 (UMLS CUI [1,1])
C1963724 (UMLS CUI [1,2])
Item
Ongoing Medication?
text
C2826666 (UMLS CUI [1,1])
C1963724 (UMLS CUI [1,2])
Eligibility Question
Code List
Ongoing Medication?
CL Item
Yes (Y)
CL Item
No (N)
Blood pressure systolic
Item
Vital signs: Blood pressure systolic
integer
C0871470 (UMLS CUI [1])
Blood pressure diastolic
Item
Vital signs: Blood pressure diastolic
integer
C0428883 (UMLS CUI [1])
Heart rate
Item
Vital signs: Heart rate
integer
C0018810 (UMLS CUI [1])
Temperature
Item
Vital signs: Temperature
float
C0005903 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial